Novel Nano Polymeric Lipid-Based Carriers for Emerging Pain Management of Rheumatoid Arthritis

Pankaj Kumar; Dhananjay kumar

Abstract

An inflammatory condition known as rheumatoid arthritis (RA) results in chronic joint inflammation, severe disability, and early death. RA is 3–5 times more common in women than in men, with a global frequency of roughly 0.3 percent–1%. The ultimate goal of RA treatment is to give symptomatic alleviation; there is no recognized cure for RA. NSAIDs are frequently used to treat RA, including indomethacin, diclofenac, ibuprofen, celecoxib, and specifies the characteristics. off-target effects are common with these powerful medications, and patient compliance suffers as a result. Additionally, non-steroidal anti-inflammatory medicines have a variety of formulation issues, including as poor bioavailability, gastrointestinal enzyme breakdown, food interactions, toxicity, and low solubility and permeability. To get over these roadblocks, researchers have turned to the topical route of drug delivery, which has higher patient compliance and avoids the first side effect that comes with traditional oral administration. Additionally, nanosized carriers such as exosomes, micro emulsifiers, nanocapsules, niosomes, solid lipid nanoparticles, and transferosomes have been built to assist drugs penetrate the skin's layers and reach the site of inflammation. These drug delivery methods are non-toxic, have a high drug encapsulation efficiency, and provide a long-term drug release. This review, which presents a landscape of topically applied Nano formulations for the symptomatic treatment of RA, discusses the impact of plan execution on the physicochemical characteristics of these niosomes in terms of particulate matter, charge density, drug - loading, and release of drug.

Abstract

Keywords